|
1
|
Reisi N, Raeissi P, Harati Khalilabad T
and Moafi A: Unusual sites of bone involvement in Langerhans cell
histiocytosis: A systematic review of the literature. Orphanet J
Rare Dis. 16(1)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sconocchia T, Foßelteder J, Sconocchia G
and Reinisch A: Langerhans cell histiocytosis: Current advances in
molecular pathogenesis. Front Immunol. 14(1275085)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Harmon CM and Brown N: Langerhans cell
histiocytosis: A clinicopathologic review and molecular
pathogenetic update. Arch Pathol Lab Med. 139:1211–1214.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zinn DJ, Chakraborty R and Allen CE:
Langerhans cell histiocytosis: Emerging insights and clinical
implications. Oncology (Williston Park). 30:122–139.
2016.PubMed/NCBI
|
|
5
|
Emile JF, Abla O, Fraitag S, Horne A,
Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab
O, Allen CE, et al: Revised classification of histiocytoses and
neoplasms of the macrophage-dendritic cell lineages. Blood.
127:2672–2681. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cao XX, Duan MH, Zhao AL, Cai H, Chen J,
Gao XM, Liu T, Cai HC, Zhang L, Sun J, et al: Treatment outcomes
and prognostic factors of patients with adult Langerhans cell
histiocytosis. Am J Hematol. 97:203–208. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Reginelli A, Pignatiello M, Urraro F,
Belfiore MP, Toni G, Vacca G and Cappabianca S: Langerhans cell
histiocytosis with uncommon liver involvement: A case report. Am J
Case Rep. 21(e923505)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sato A, Kobayashi M, Yusa N, Ogawa M,
Shimizu E, Kawamata T, Yokoyama K, Ota Y, Ichinohe T, Ohno H, et
al: Clinical and prognostic features of Langerhans cell
histiocytosis in adults. Cancer Sci. 114:3687–97. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hashimoto K, Nishimura S, Sakata N, Inoue
M, Sawada A and Akagi M: Treatment outcomes of langerhans cell
histiocytosis: A retrospective study. Medicina (Kaunas).
57(356)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Murakami I, Oh Y, Morimoto A, Sano H,
Kanzaki S, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K,
et al: Acute-phase ITIH4 levels distinguish multi-system from
single-system Langerhans cell histiocytosis via plasma peptidomics.
Clin Proteomics. 12(16)2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ismail MB, Åkefeldt SO, Lourda M, Gavhed
D, Aricò M, Henter JI, Delprat C and Valentin H: High levels of
plasma interleukin-17A are associated with severe neurological
sequelae in Langerhans cell histiocytosis. Cytokine.
126(154877)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lian C, Lu Y and Shen S: Langerhans cell
histiocytosis in adults: A case report and review of the
literature. Oncotarget. 7:18678–18683. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Simko SJ, Garmezy B, Abhyankar H, Lupo PJ,
Chakraborty R, Lim KP, Shih A, Hicks MJ, Wright TS, Levy ML, et al:
Differentiating skin-limited and multisystem Langerhans cell
histiocytosis. J Pediatr. 165:990–996. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Vassallo R, Ryu JH, Schroeder DR, Decker
PA and Limper AH: Clinical outcomes of pulmonary Langerhans' cell
histiocytosis in adults. N Engl J Med. 346:484–490. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Allen CE, Merad M and McClain KL:
Langerhans-cell histiocytosis. N Engl J Med. 379:856–868.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Awada G, Seremet T, Fostier K, Everaert H
and Neyns B: Long-term disease control of Langerhans cell
histiocytosis using combined BRAF and MEK inhibition. Blood Adv.
2:2156–2158. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Messinger YH, Bostrom BC, Olson DR, Gossai
NP, Miller LH and Richards MK: Langerhans cell histiocytosis with
BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK
inhibitor trametinib. Pediatr Blood Cancer.
67(e28712)2020.PubMed/NCBI View Article : Google Scholar
|
